Despite experiencing significant reductions in triglycerides, patients with triglycerides over 150 mg/dL and a high risk of ...
The liver APOC3-targeted RNA interference agent plozasiran proved its triglyceride-lowering effects in people with mixed hyperlipidemia in the phase IIb MUIR trial. In such individuals, known to be at ...
LipiPB Red shows longer fluorescence lifetimes in stable lipid droplets (red) and shorter lifetimes as they undergo degradation (blue). This probe revealed that lipid droplets sequentially degrade, ...
The researchers identified a driving force behind the condition, opening up a potential target for new therapies.
Despite experiencing significant reductions in triglycerides, patients with triglycerides over 150 mg/dL and a high risk of ...
Both doses of olezarsen significantly reduced triglyceride levels at 6 months compared with placebo (placebo-adjusted reduction, 50mg: 58%; 80mg: 61%; P .0001). Topline data were announced from a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results